| Feature Type | Standardized | Nominal ANOVA | ||||
|---|---|---|---|---|---|---|
| mRNA | ELCPK | CTRPv2 | pan-cancer | AAC | 0.014 | 0.8 |
| mRNA | BRD-K88742110 | CTRPv2 | pan-cancer | AAC | -0.01 | 0.8 |
| mRNA | BCL-LZH-4 | CTRPv2 | pan-cancer | AAC | 0.014 | 0.8 |
| mRNA | FH535 | GDSC1000 | pan-cancer | AAC | 0.0087 | 0.8 |
| mRNA | dabrafenib | CTRPv2 | pan-cancer | AAC | 0.012 | 0.8 |
| mRNA | navitoclax:MST-312 (1:1 mol/mol) | CTRPv2 | pan-cancer | AAC | 0.0097 | 0.8 |
| mRNA | QL-XII-61 | GDSC1000 | pan-cancer | AAC | -0.012 | 0.8 |
| mRNA | GSK1070916 | GDSC1000 | pan-cancer | AAC | 0.0077 | 0.8 |
| mRNA | tipifarnib | CTRPv2 | pan-cancer | AAC | -0.008 | 0.8 |
| mRNA | Sorafenib | CCLE | pan-cancer | AAC | 0.012 | 0.8 |